New data from GAP landmark trial confirm Grazax prevents asthma symptoms in children
Patients showed modified immunological responses to grass pollen, indicating inhibition of disease progression.
ALK has presented new data from the Grazax Asthma Prevention (GAP) trial with Grazax, ALK's allergy immunotherapy tablet against grass pollen allergy.
The data, presented at the 2016 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Vienna, confirm that Grazax can prevent asthma symptoms, as well as offering sustained relief from grass allergy symptoms. Moreover, immunological findings were highly supportive of the disease-modifying nature of the treatment.
The GAP trial is the largest allergy immunotherapy trial ever conducted in children and investigated the effect of Grazax versus placebo on the risk of developing asthma. It involved a 3-year treatment phase and a 2-year follow-up phase and included 812 children aged 5-12 years at the start of treatment.
The detailed analysis of the GAP trial results confirmed that treatment with Grazax prevented asthma symptoms in children:
In addition, the treatment effect increased with time and was apparent both during the grass pollen season and during winter.
Moreover, the GAP trial demonstrated the efficacy of Grazax on grass allergic rhinoconjunctivitis in children, with benefits persisting for 2 years after treatment.
The trial also yielded new data, with the detailed analysis of patients' immunological response supportive of early intervention with Grazax.
Two years after treatment, Grazax-treated children were less IgE sensitised to grass pollen and had lower total IgE, both indicating a reduced allergic response. Grazax patients also had higher grass pollen-specific IgG4 levels, indicating raised immunological tolerance. Meanwhile, the wheal size from the skin prick test using grass allergen - an indicator of the extent of an allergic reaction - was significantly smaller for the Grazax group than for the placebo group.
The continued analysis of data from the GAP landmark trial follows the initial release of top-line data in January 2016. This showed that Grazax treatment significantly reduced the proportion of children experiencing asthma symptoms or using asthma medication, however there was no detectable effect in terms of time to the first diagnosis of reversible impairment of lung function and the primary endpoint of the trial was therefore not met. The safety and tolerability of Grazax were both favourable and in line with previous studies, with no new or unexpected findings.
Erkka Valovirta, paediatric allergist, Adjunct Professor at the University of Turku, Finland, and principal investigator for the GAP trial, said: "These results further enhance our understanding of allergic disease and the benefit of Grazax treatment for children whose grass allergy is not well controlled by conventional therapies. For the first time, we also see that, by treating paediatric patients early enough, we can change the trajectory of their immune system development."
He added: "The GAP trial provides further evidence that it is possible to reprogramme the allergic immune response. It also suggests there may be benefit in offering early treatment to children to minimise the risk of a lifetime of respiratory disease."
Henrik Jacobi, ALK's Executive Vice President of Research and Development, said: "We are particularly excited about these new results. They confirm the benefit of Grazax in offering sustained relief from childhood allergic rhinitis both during and after treatment. They also provide the strongest evidence yet for the early use of Grazax in children with moderate-to-severe allergies and who are at risk of developing asthma."He continued: "These insights also reaffirm ALK's position as the leading innovator in allergy treatment and further advance our understanding of the way the human immune system responds to specific allergens."
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance